Drug Profile
Research programme: antibacterials - GPC Biotech/Karo Pharma
Latest Information Update: 21 Dec 2016
Price :
$50
*
At a glance
- Originator GPC Biotech AG; Karo Bio
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Bacterial infections
Most Recent Events
- 13 Jun 2002 Discontinued - Preclinical for Bacterial infections in USA (unspecified route)
- 17 Jul 2000 Preclinical development for Bacterial infections in USA (Unknown route)